Going Generic | GenomeWeb

Going Generic

Philadelphia-based Mylan and India-based Biocon are teaming up to develop generic biotech drugs. "It makes sense that Mylan, which is an expert in making generic copies of traditional drugs, would partner with an outside firm that focuses on biotech. By the same token, cracking the market for generic biotechs in the developed world might also be tricky - so it makes sense that an Indian firm might want a U.S. partner," says the Wall Street Journal Health Blog.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.